XML 18 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations (unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
REVENUES        
Product revenue, net $ 0 $ 0 $ 0 $ 4,140,090
OPERATING EXPENSES        
Cost of products sold 0 0 0 97,637
Research and development 3,755,158 7,159,686 12,928,391 17,728,516
Selling, general and administrative 1,474,019 2,033,410 5,176,794 8,266,267
Loss (Gain) on sale of Vyleesi 0 25,202 (2,500,000) (7,798,280)
Gain on purchase commitment (416,000) 0 (416,000) 0
Total operating expenses 4,813,177 9,218,298 15,189,185 18,294,140
Loss from operations (4,813,177) (9,218,298) (15,189,185) (14,154,050)
OTHER INCOME (EXPENSE)        
Investment income 31,452 139,273 139,072 272,929
Foreign currency transaction (loss) gain (27,900) 215,600 (15,900) 68,653
Interest expense (1,795) (1,254) (11,538) (13,741)
Offering expenses 0 0 0 (696,912)
Change in fair value of warrant liabilities 0 429,029 0 6,962,562
Total other income (expense), net 1,757 782,648 111,634 (7,331,633)
NET LOSS $ (4,811,420) $ (8,435,650) $ (15,077,551) $ (21,485,683)
Basic and diluted net loss per common share $ (0.18) $ (0.53) $ (0.68) $ (1.53)
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share 26,344,584 15,792,421 22,245,153 14,013,848